Utilization of cefepime therapeutic drug monitoring in febrile neutropenia patients with hematologic malignancies
Journal of Oncology Pharmacy Practice · 2024
DOI: 10.1177/10781552231213883 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Oncology Pharmacy Practice, 2024. Verfasst von Emma F Lodl und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Cefepime, Hematologic Neoplasms, Drug Monitoring, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
Introduction
Cefepime is a fourth-generation cephalosporin and is a workhorse for the empiric treatment of febrile neutropenia (FN). Beta-lactam therapeutic drug monitoring (TDM) has emerged as a dose optimization strategy in patient populations with altered kinetics. Prior literature has demonstrated that patients with FN exhibit augmented renal clearance which may lead to subtherapeutic drug concentrations with standard dosing regimens. The aim of this study was to evaluate pharmacokinetic/pharmacodynamic (PK/PD) target attainment and clinical outcomes in patients with hematologic malignancies and FN who were treated empirically with cefepime.
Methods
This was a prospective, single-center study of adults with hematologic malignancies and FN admitted to the inpatient unit. The primary outcome was PK/PD target attainment (defined as 100% free time greater than minimum inhibitory concentration (100% fT > MIC)). Secondary clinical outcomes were time to defervescence, time to ANC recovery, in-hospital mortality, and cefepime failure.
Results
There were 55 patients in our study. Forty-three (78%) patients achieved the primary outcome of PK/PD target attainment. The mean time to defervescence was similar between those that achieved PK/PD target attainment and those that did not (95% CI −0.75 to 1.25, p = 0.62).
Conclusions
This study showed that standard cefepime dosing in patients with hematologic malignancies and FN does not result in achievement of 100% fT > MIC in all patients. Patients in the group that did not achieve PK/PD target attainment were younger with increased creatinine clearance, indicating that cefepime TDM may be especially beneficial in these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- University of Florida College of Pharmacy, Gainesville, FL, USA.
- UF Health Shands Hospital, Gainesville, FL, USA.
ORCID-Profile: Emma F Lodl
Zitieren
APA
Lodl, E. F., Alshaer, M. H., Adams, C. B., Richards, A., Peloquin, C., & Venugopalan, V. (2024). Utilization of cefepime therapeutic drug monitoring in febrile neutropenia patients with hematologic malignancies. Journal of Oncology Pharmacy Practice. https://doi.org/10.1177/10781552231213883
Vancouver
Lodl EF, Alshaer MH, Adams CB, Richards A, Peloquin C, Venugopalan V. Utilization of cefepime therapeutic drug monitoring in febrile neutropenia patients with hematologic malignancies. Journal of Oncology Pharmacy Practice. 2024. doi:10.1177/10781552231213883
BibTeX
@article{Lodl2024,
author = {Lodl, Emma F and Alshaer, Mohammad H and Adams, C Brooke and Richards, Ashley and Peloquin, Charles and Venugopalan, Veena},
title = {Utilization of cefepime therapeutic drug monitoring in febrile neutropenia patients with hematologic malignancies},
journal = {Journal of Oncology Pharmacy Practice},
year = {2024},
doi = {10.1177/10781552231213883}
}
EUVIMED